Biden reveals aggressive prostate cancer that has metastasized to his bones.
All News
Advertisement
HHS announces plan to create ‘most-favored-nation’ cost scale so U.S. is not subsidizing drug prices in other countries.
Advertisement
Avoid regret: 10 things every physician should know before choosing an electronic health record (EHR) platform.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
Advertisement
A new national report finds primary care physicians diagnose 41% of pediatric major depressive disorder cases, often before crisis hits.
Remote support is helping primary care practices reduce administrative stress, allowing physicians to focus more on patient care.
How do hospice services for end of life align with value-based care? Here’s what primary care physicians should know.
Atia Vision's OmniVu lens system promises a breakthrough in cataract surgery with enhanced vision restoration.
Advertisement
The former president likely will have drug therapy to lower his testosterone levels, but there are other treatment options.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
An expert physician panel discusses how vaccine policy has gone wrong under the Trump administration, why misinformation has flourished and what individual physicians can do to win back patient trust.
Daniel Isaac, DO, MS, an oncologist/hematologist, discusses the publicly disclosed diagnosis of prostate cancer in former President Joe Biden.
Daniel Isaac, DO, MS, an oncologist/hematologist, discusses the publicly disclosed diagnosis of prostate cancer in former President Joe Biden.
Daniel Isaac, DO, MS, an oncologist/hematologist, discusses the publicly disclosed diagnosis of prostate cancer in former President Joe Biden.
Daniel Isaac, DO, MS, an oncologist/hematologist, discusses the publicly disclosed diagnosis of prostate cancer in former President Joe Biden.
Daniel Isaac, DO, MS, an oncologist/hematologist, discusses the publicly disclosed diagnosis of prostate cancer in former President Joe Biden.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
Lack of awareness leads many to overlook these potent financial tools
A new study in JAMA Health Forum finds women primary care physicians earn more under value-based models — while delivering better outcomes and fewer hospital visits.
Compounded GLP-1 RA drugs: Are GLP-1 RA drugs the biggest phenomenon in American health care? Part 1
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
U.S. tariffs are disrupting European medtech growth, forcing firms to adapt supply chains and prioritize cost optimization amid rising challenges and uncertainties.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
Jeffrey A. Singer, M.D., a general surgeon and senior fellow at the Cato Institute, joins the show to talk patient autonomy in health care.
Fujirebio Diagnostics’ test, which received 510k clearance Friday, will “assist physicians and patients to obtain an AD diagnosis in early stages of the disease.”
Advertisement
Advertisement
Trending on Medical Economics
1
Remote monitoring boosts Medicare revenue by 20% for primary care practices, study finds
2
10 U.S. cities with the worst inflation in 2025
3
Preview: Can independent medical practices still succeed? Our expert panel
4
As health systems grow, low-income Medicare patients lose ground, RAND study finds
5
